Moderna Stock Quote and Performance Overview

Moderna's stock has been on a wild ride since its IPO in 2018, with a peak price of over $230 per share in 2021.

The company's mRNA-based COVID-19 vaccine, known as Spikevax, has been a game-changer in the fight against the pandemic.

Moderna's stock price has been volatile, with a high of $230.10 on February 16, 2021, and a low of $38.55 on March 18, 2020.

As of the latest available data, Moderna's market capitalization is over $130 billion.

Curious to learn more? Check out: Has Moderna Been Approved for under 18?

Moderna has made a significant announcement that could impact investors. The company has entered into an Agreement that provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply.

This Agreement will give countries access to pre-filled syringe vaccine formats, which could be a game-changer for global vaccine distribution.

Moderna stock is trading higher on Tuesday, with a notable session volume of 8.0 million as per data from Benzinga Pro.

This significant trading activity is likely a result of various market trends and investor sentiment.

Tuesday's market is off to a strong start with Moderna Inc MRNA stock trading higher, thanks in part to a session volume of 8.0 million as seen in data from Benzinga Pro.

This uptick in trading activity is a good sign for investors, indicating a potential increase in interest in the company's stock.

The session volume of 8.0 million is a significant number, suggesting that many investors are actively buying and selling MRNA stock on Tuesday.

In the competitive landscape of the market, companies like Amazon and Walmart are major players that are worth noting. They have a significant presence in the online shopping space, with Amazon's sales reaching $386 billion in 2020.

Their business models are centered around offering low prices and fast shipping, which has led to a significant increase in e-commerce sales. This shift in consumer behavior has forced traditional brick-and-mortar stores to adapt and invest in their own e-commerce platforms.

Recommended read: Amazon Stock Price Google Finance

Companies like Target and Costco are also competing in this space, offering a wide range of products and services to customers. Their success is largely due to their ability to provide a seamless shopping experience across both online and offline channels.

The rise of digital marketplaces has also given rise to new competitors like eBay and Etsy, which specialize in niche products and services. These platforms have created new opportunities for small businesses and entrepreneurs to reach a wider audience.

The competition in the market is fierce, but it's also driving innovation and improvement in the services offered by these companies.

Explore further: New York Community Bank Stock Quote

Moderna's stock performance has been quite volatile over the past few years. The current share price is $41.65.

The 52-week high for Moderna's stock was a whopping $170.47, while the 52-week low was $31.94. That's a significant difference of $138.53.

Here's a breakdown of Moderna's stock performance over the past year:

The S&P 500 had a mixed start to the week, but ultimately fell by 0.2% on Monday.

Investors unloaded key tech shares that have been driving the bull market, contributing to the decline.

The Nasdaq Composite dropped 0.8% on the same day, showing a more significant decline than the S&P 500.

Moderna's stock has taken a hit, plummeting to post-COVID lows after a disappointing revenue outlook.

The company's stock price dropped significantly due to a lackluster revenue forecast. Moderna's stock tumbled after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.

This decline is a stark contrast to the company's previous performance, where its stock had been rising steadily.

Suggestion: Moderna Booster

If you're looking to get a sense of a company's stock performance, one key metric to consider is the 52-week high and low. Moderna's stock has seen a significant range, with a 52-week high of $170.47 and a low of $31.94.

The current share price of Moderna is $41.65, which is a far cry from its 52-week high. This highlights the volatility of the stock market and the importance of doing your research before investing.

Beta measures a stock's volatility relative to the overall market, and Moderna's beta is 1.59. This means that Moderna's stock is more volatile than the overall market.

In the past month, Moderna's stock has seen a 3.79% increase, which is a relatively positive trend. However, over the past three months, the stock has actually decreased by 23.89%.

Here's a summary of Moderna's stock performance over the past year and beyond:

Overall, Moderna's stock performance has been quite variable, making it essential to stay up-to-date with the latest developments and trends in the market.

Moderna, Inc. is a biotechnology company that discovers, develops, and commercializes messenger RNA therapeutics and vaccines.

Their products treat a range of diseases, including infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases.

Moderna has developed respiratory vaccines, including COVID-19, influenza, and respiratory syncytial virus vaccines.

Their latent vaccines target diseases like cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus.

Moderna's work has a global reach, with operations in the United States, Europe, and internationally.

Moderna reported 2024 product sales of $3.0-3.1 billion, with $1.7 billion coming from the US market.

The company ended 2024 with a significant cash balance of approximately $9.5 billion.

Moderna projects 2025 revenue of $1.5-2.5 billion, mainly from Spikevax and mRESVIA sales.

The company expects to end 2025 with a cash balance of $6.0 billion.

Moderna plans to implement significant cost reductions, totaling $1.0 billion in 2025 and an additional $0.5 billion in 2026.

The company has made progress in its pipeline, with the FDA reviewing its next-generation COVID-19 vaccine, mRNA-1283, with a PDUFA date of May 31, 2025.

Explore further: Natural Balance

Moderna reported 2024 product sales of $3.0-3.1 billion, with $1.7 billion of that coming from the US. The company ended 2024 with approximately $9.5 billion in cash.

Moderna projects 2025 revenue of $1.5-2.5 billion, mainly from Spikevax and mRESVIA sales. The company expects to have a year-end cash balance of $6.0 billion.

The company plans significant cost reductions, with $1.0 billion in cuts planned for 2025 and an additional $0.5 billion in 2026. This will help the company stay financially stable.

Moderna is also making progress in its pipeline, with a next-generation COVID-19 vaccine (mRNA-1283) currently under FDA review. The PDUFA date for this vaccine is May 31, 2025.

The company has also seen positive Phase 3 data for its flu/COVID combination vaccine. This is a promising development in the fight against these diseases.

Moderna is also working on vaccines for CMV and norovirus, with ongoing trials for these vaccines. This is an exciting area of research, as these diseases can have a significant impact on public health.

The company has completed enrollment in a Phase 3 melanoma trial with individualized neoantigen therapy, which is a promising area of research in cancer treatment.

Moderna has secured $590 million in federal funding to develop a bird flu vaccine. This significant investment will support the late-stage development and licensure of pre-pandemic mRNA-based vaccines.

The company plans to use this funding to advance the development of its mRNA bird flu vaccine. This is a major step in tackling increasing infections in humans caused by the bird flu virus.

Moderna's mRNA technology has shown promise in developing effective vaccines. With this funding, the company aims to bring its bird flu vaccine to market and provide a vital tool in the fight against this serious disease.

The $590 million in funding will also support the development of other pre-pandemic mRNA-based vaccines. This is a strategic move by the company to expand its vaccine portfolio and address emerging public health threats.

Moderna's financial health is also a positive sign, with a projected 2025 revenue of $1.5-2.5 billion. This revenue, along with a significant reduction in costs, will help the company achieve a year-end cash balance of $6.0 billion.